drugset / Trial / NCT00868959

Lurasidone - A 24-week Extension Study of Patients With Bipolar I Depression

NCT00868959

Phase 3 Completed 817 enrolled Sumitomo Pharma America, Inc.
NaSingle-groupOpen-labelTreatment

Summary

This clinical study is designed to test the hypothesis that lurasidone is effective, tolerable, and safe for the treatment of patients with bipolar I depression

Timeline

Start
2009-04
Primary completion
2013-02
Completion
2013-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Lurasidone Small molecule 20 mg
Subject Lurasidone Small molecule 120 mg

Indications